Tesamorelin

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (1-44), modified with a trans-3-hexenoyl group at the N-terminus to slow enzymatic degradation. It is a 44-residue peptide supplied as a lyophilised solid. Its size places greater demands on analytical verification than short fragments: reversed-phase HPLC purity, mass spectrometric identity confirmation and, where specified, peptide content determination are all relevant, and a purity figure without a stated method is uninformative for a peptide of this length. Values on this record are transcribed from supplier documentation.

Tesamorelin is unusual in this catalogue in that it has a completed regulatory development history. It was developed as a GHRH analogue, evaluated in multi-site randomised placebo-controlled trials, and approved by the FDA in 2010 for a specific indication in a defined patient population under medical supervision. That approval concerns a licensed pharmaceutical product prescribed and administered clinically. It does not extend to research-grade material, and nothing on this page describes clinical use.

The development history also illustrates why regulatory review matters as an evidence filter. Between first-in-human work and approval, the compound was tested against placebo in adequately powered populations, its manufacturing was characterised, and the resulting label was constrained to the population and endpoint actually studied. Most peptides discussed on this site never entered that filter, and the difference in what can honestly be claimed about them is a direct consequence.

The mechanism is the best characterised of any compound on this site: binding at the GHRH receptor on anterior pituitary somatotrophs, stimulating endogenous growth hormone release in a pulsatile pattern with downstream elevation of IGF-1. Published work covers receptor pharmacology, dose-exposure relationships, effects on visceral adipose tissue measured by imaging, and effects on glucose parameters and IGF-1 levels measured in trial populations.

A related strand of published work concerns the pulsatility of hormone release. GHRH analogues act upstream of the pituitary and therefore preserve the pulsatile secretory pattern and the negative feedback loops that constrain it, in contrast to direct administration of the hormone itself. This mechanistic distinction is well described in the endocrinology literature and is one of the clearer examples in this catalogue of a mechanism that is understood rather than merely proposed.

Multiple randomised, double-blind, placebo-controlled trials with hundreds of participants each, plus extension phases, support the pharmacology in the studied population. Effects on the primary imaging endpoint were statistically significant and reproduced across separate trials. Pharmacokinetics, immunogenicity and adverse-event profiles were characterised to regulatory standard. This is a body of evidence of a completely different quality from the preclinical literature that supports most peptides in this catalogue, and the contrast is worth stating plainly.

The trial programme also produced information of a kind rarely available for compounds in this catalogue: pre-specified statistical analysis plans, independent data monitoring, published discontinuation rates, and reporting of adverse events by frequency and severity in both arms. Anti-drug antibody formation was measured rather than assumed absent. Effects were reported alongside the proportion of participants who did not respond, which is the figure most secondary summaries omit. When evaluating any supplier's description of this compound, the presence or absence of that kind of detail is a fast way to judge whether the description was written from the primary literature or from marketing copy.

The strength of the evidence is narrow as well as real. Trials were conducted in one specific patient population with one specific endpoint; extrapolation to other populations is not supported by that data. Effects were not durable after discontinuation in the studied trials, which is a finding often omitted from secondary summaries. Elevation of IGF-1 and effects on glucose tolerance were observed and required monitoring in the trial setting. Long-term outcome data beyond the trial windows are limited. There are no trials in healthy participants supporting any other use, and no data of any kind establish equivalence between research-grade material and the licensed product, which differ in formulation, manufacturing controls and release testing.

The gap between the licensed product and research-grade material deserves particular emphasis for this compound precisely because the clinical evidence is real. A licensed injectable is manufactured under pharmaceutical quality systems with controls on sterility, endotoxin, aggregation, related substances and container closure, and it is released against a validated specification. Research-grade material is released against a supplier specification with a scope the buyer must read for themselves. Trial results describe the former. Nothing in the published record characterises the latter, and treating the two as equivalent is an unsupported substitution.

Store the lyophilised solid per the storage conditions on this record, protected from light and moisture, and equilibrate the sealed vial before opening. Longer peptides are more prone to aggregation and to oxidation at susceptible residues; repeated freeze-thaw of reconstituted material and agitation are the handling variables most often associated with analytical failure. This section addresses laboratory handling of the material as supplied and contains no preparation or administration procedure.

Indexed citations with verified PMIDs appear below and link to the primary PubMed records. See testing methodology for the analytical basis of these values and sourcing standards for the documentation expected with every batch.